Kura Oncology (NASDAQ: KURA) has recently received a number of price target changes and ratings updates:
- 10/15/2026 – Kura Oncology had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/14/2026 – Kura Oncology had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 10/14/2026 – Kura Oncology was given a new $24.00 price target by Barclays.
- 10/14/2026 – Kura Oncology was given a new $24.00 price target by Deutsche Bank Aktiengesellschaft.
- 10/14/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citigroup.
- 10/5/2026 – Kura Oncology had its “buy” rating reaffirmed by UBS Group.
- 10/1/2026 – Kura Oncology is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $30.00 price target on the stock.
Insider Buying and Selling at Kura Oncology
In other news, SVP Thomas Doyle sold 4,607 shares of the company’s stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $10.50, for a total transaction of $48,373.50. Following the sale, the senior vice president owned 142,428 shares in the company, valued at $1,495,494. This represents a 3.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Kathleen Ford sold 3,668 shares of the stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total value of $39,431.00. Following the completion of the sale, the chief operating officer directly owned 142,986 shares of the company’s stock, valued at approximately $1,537,099.50. The trade was a 2.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 153,881 shares of company stock valued at $1,708,183 in the last ninety days. Insiders own 7.60% of the company’s stock.
Kura Oncology, Inc (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.
Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.
Read More
- Five stocks we like better than Kura Oncology
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Kura Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.
